Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Oogenesis02:07

Oogenesis

68.7K
In human women, oogenesis produces one mature egg cell or ovum for every precursor cell that enters meiosis. This process differs in two unique ways from the equivalent procedure of spermatogenesis in males. First, meiotic divisions during oogenesis are asymmetric, meaning that a large oocyte (containing most of the cytoplasm) and minor polar body are produced as a result of meiosis I, and again following meiosis II. Since only oocytes will go on to form embryos if fertilized, this unequal...
68.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ESHRE guideline: ovarian stimulation for IVF/ICSI: an update in 2025†.

Human reproduction (Oxford, England)·2026
Same author

Training of young medical professionals: implementation of modern training concepts, taking into account the changed framework conditions for training-a pilot project for operational subjects.

Archives of gynecology and obstetrics·2024
Same author

Oral dydrogesterone versus micronized vaginal progesterone for luteal phase support: a double-blind crossover study investigating pharmacokinetics and impact on the endometrium.

Human reproduction (Oxford, England)·2023
Same author

Aneuploidy in oocytes from women of advanced maternal age: analysis of the causal meiotic errors and impact on embryo development.

Human reproduction (Oxford, England)·2023
Same author

ESHRE good practice recommendations on recurrent implantation failure.

Human reproduction open·2023
Same author

Effect of the oxytocin receptor antagonist nolasiban on pregnancy rates in women undergoing embryo transfer following IVF: analysis of three randomised clinical trials.

Human reproduction (Oxford, England)·2021
Same journal

[Pelvic floor in pregnancy and after child birth: recommendations of the AUG Committee. Expert correspondence no. 29 of 31 July 2009].

Gynakologisch-geburtshilfliche Rundschau·2010
Same journal

[Water birth: control of infection and contraindications. Expert correspondence no. 27 of 26 May 2009].

Gynakologisch-geburtshilfliche Rundschau·2010
Same journal

[Current treatment options in postpartum hemorrhage. Expert correspondence no. 26 of 26 May 2009. ].

Gynakologisch-geburtshilfliche Rundschau·2010
Same journal

[Off label use of drugs in obstetric gynecology. 23rd consensus of of experts 19 October 2007].

Gynakologisch-geburtshilfliche Rundschau·2010
Same journal

[Hyperreactive luteomas during pregnancy--symptoms and complications: a case report].

Gynakologisch-geburtshilfliche Rundschau·2010
Same journal

[Paget disease of the vulva: resolution after local treatment with imiquimod--report of a case and review of the literature].

Gynakologisch-geburtshilfliche Rundschau·2010
See all related articles

Related Experiment Video

Updated: Jan 2, 2026

Fertility Preservation Through Oocyte Vitrification: Clinical and Laboratory Perspectives
08:46

Fertility Preservation Through Oocyte Vitrification: Clinical and Laboratory Perspectives

Published on: September 16, 2021

6.5K

[New developments in ovarian stimulation].

G Griesinger1, K Diedrich

  • 1Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Lübeck, Deutschland. georg.griesinger@frauenklinik.uni-luebeck.de

Gynakologisch-Geburtshilfliche Rundschau
|April 7, 2009
PubMed
Summary
This summary is machine-generated.

New developments in ovarian stimulation aim to improve in vitro fertilization (IVF) effectiveness and patient safety. These include preventing ovarian hyperstimulation syndrome (OHSS) and reducing injection frequency with long-acting hormones.

More Related Videos

OP-IVM: Combining In vitro Maturation after Oocyte Retrieval with Gynecological Surgery
05:31

OP-IVM: Combining In vitro Maturation after Oocyte Retrieval with Gynecological Surgery

Published on: May 9, 2021

4.5K
Fertility Preservation in Patients with Severe Ovarian Dysfunction
12:03

Fertility Preservation in Patients with Severe Ovarian Dysfunction

Published on: March 25, 2021

4.9K

Related Experiment Videos

Last Updated: Jan 2, 2026

Fertility Preservation Through Oocyte Vitrification: Clinical and Laboratory Perspectives
08:46

Fertility Preservation Through Oocyte Vitrification: Clinical and Laboratory Perspectives

Published on: September 16, 2021

6.5K
OP-IVM: Combining In vitro Maturation after Oocyte Retrieval with Gynecological Surgery
05:31

OP-IVM: Combining In vitro Maturation after Oocyte Retrieval with Gynecological Surgery

Published on: May 9, 2021

4.5K
Fertility Preservation in Patients with Severe Ovarian Dysfunction
12:03

Fertility Preservation in Patients with Severe Ovarian Dysfunction

Published on: March 25, 2021

4.9K

Area of Science:

  • Reproductive Endocrinology and Infertility
  • Assisted Reproductive Technologies (ART)

Context:

  • Ovarian stimulation is crucial for in vitro fertilization (IVF) success but carries risks, patient burden, and costs.
  • Continuous improvement in ovarian stimulation protocols is necessary to enhance safety and efficacy.
  • Existing protocols require frequent injections and carry risks like ovarian hyperstimulation syndrome (OHSS).

Purpose:

  • To review significant advancements in ovarian stimulation for IVF.
  • To discuss novel strategies for mitigating risks and improving patient experience in ovarian stimulation.

Summary:

  • Gonadotropin-releasing hormone agonist bolus dose effectively prevents OHSS, replacing human chorionic gonadotropin.
  • Long-acting follicle-stimulating hormone (FSH-CTP) allows for reduced injection frequency (7-day stimulation) with comparable pregnancy rates to daily injections.
  • Development of orally active non-peptide mimetics for luteinizing hormone and FSH is ongoing, with limited human data available.

Impact:

  • Reduced incidence of OHSS, a severe complication of ovarian stimulation.
  • Improved patient compliance and reduced treatment burden through less frequent injections.
  • Potential for more convenient and accessible fertility treatments in the future with oral medications.